Abstract

Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the management of hypertension. It is well absorbed following oral administration, with rather poor bioavailability of about 25 %. Peak plasma concentration of valsartan occurs 2-4 hours after ingestion. Optimized VAL-SLN was prepared by pre-emulsion sonication method and sprays dried to improve the handling processing and stability. Solid state studies such as Infra Red Spectroscopy and Differential Scanning Calorimetry indicated absence of any chemical interaction between valsartan and the lipids. Prepared patches possess satisfactory physiochemical characteristics. The absorption of VAL-SLN patches (F-4) resulted in 2.02 fold increase in bioavailability as compared to oral capsule formulation. Results of pharmacokinetic studies indicated that the solid lipid nanoparticles can be successfully used as potential vehicles for enhancement of bioavailability of poorly soluble drugs. The aim of the study was to study the enhancement of bioavailability of valsartan from transdermally applied solid lipid nanoparticles. Dr. Reena Antony"Improvement of Bioavailability of Valsartan through Novel Transdermal Drug Delivery System" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-1 | Issue-6 , October 2017, URL: http://www.ijtsrd.com/papers/ijtsrd2508.pdf http://www.ijtsrd.com/pharmacy/other/2508/improvement-of-bioavailability-of-valsartan-through-novel-transdermal-drug-delivery-system/dr-reena-antony

Authors and Affiliations